Edition:
United States

Cara Therapeutics Inc (CARA.OQ)

CARA.OQ on NASDAQ Stock Exchange Global Market

19.67USD
4:00pm EDT
Change (% chg)

$-0.29 (-1.45%)
Prev Close
$19.96
Open
$20.10
Day's High
$20.33
Day's Low
$19.38
Volume
122,822
Avg. Vol
271,208
52-wk High
$24.30
52-wk Low
$11.12

Latest Key Developments (Source: Significant Developments)

Cara Therapeutics And Vifor Fresenius Medical Care Renal Pharma Enter Into Ex-U.S. Licensing Agreement
Wednesday, 23 May 2018 06:00am EDT 

May 23 (Reuters) - Cara Therapeutics Inc ::CARA THERAPEUTICS AND VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA (VFMCRP) ENTER INTO EX-U.S. LICENSING AGREEMENT TO COMMERCIALIZE KORSUVA™ INJECTION IN DIALYSIS PATIENTS WITH PRURITUS.CARA THERAPEUTICS INC - CARA ELIGIBLE FOR UP TO $470 MILLION IN REGULATORY AND COMMERCIAL MILESTONES.CARA THERAPEUTICS INC - VFMCRP TO COMMERCIALIZE KORSUVA INJECTION WORLDWIDE EXCEPT IN U.S., JAPAN AND SOUTH KOREA.CARA THERAPEUTICS INC - CARA RECEIVES UPFRONT PAYMENT OF $50 MILLION IN CASH AND AN EQUITY INVESTMENT OF $20 MILLION.CARA THERAPEUTICS INC - CARA IS ELIGIBLE TO RECEIVE TIERED ROYALTIES BASED ON NET SALES OF KORSUVA INJECTION IN LICENSED TERRITORIES.CARA THERAPEUTICS INC - CARA WILL SOLELY PROMOTE KORSUVA INJECTION IN ALL NON-FMC CLINICS IN U.S. AND RETAIN ALL PROFITS FROM THOSE SALES.  Full Article

Cara Therapeutics Reports Q4 Loss Per Share $0.43
Thursday, 15 Mar 2018 04:01pm EDT 

March 15 (Reuters) - Cara Therapeutics Inc ::CARA THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.43.Q4 EARNINGS PER SHARE VIEW $-0.40 -- THOMSON REUTERS I/B/E/S.‍COMPANY DID NOT RECOGNIZE ANY REVENUES DURING Q4 OF 2017 OR 2016​.  Full Article

Cara Therapeutics Inc reports Q3 loss per share $0.38
Thursday, 2 Nov 2017 04:01pm EDT 

Nov 2 (Reuters) - Cara Therapeutics Inc :Cara Therapeutics Inc reports third quarter 2017 financial results.Q3 loss per share $0.38.Q3 earnings per share view $-0.34 -- Thomson Reuters I/B/E/S.Cara Therapeutics Inc - expects existing cash and cash equivalents, among others to be sufficient to fund operating expenses, capex requirements into 2019​.  Full Article

Cara Therapeutics Q2 loss per share $0.29
Thursday, 3 Aug 2017 04:01pm EDT 

Aug 3 (Reuters) - Cara Therapeutics Inc ::Cara Therapeutics reports second quarter 2017 financial results.Q2 loss per share $0.29.Q2 earnings per share view $-0.62 -- Thomson Reuters I/B/E/S.Cara-‍ expects existing cash, cash equivalents, available-for-sale marketable securities to be sufficient to fund operating expenses, capex requirements into 2019​.  Full Article

Cara Therapeutics appoints Mani Mohindru CFO
Tuesday, 1 Aug 2017 07:00am EDT 

Aug 1 (Reuters) - Cara Therapeutics Inc ::Cara Therapeutics appoints Mani Mohindru, Ph.D., chief financial officer.Josef Schoell, who has held CFO position at Cara for more than a decade, will be retiring.Most recently, Mohindru served as chief strategy officer at Curis, Inc.  Full Article

Cara Therapeutics says ‍phase 1 results showed all four tablet strengths of oral CR845 were generally well-tolerated​
Wednesday, 12 Jul 2017 07:00am EDT 

July 12 (Reuters) - Cara Therapeutics Inc :Cara Therapeutics announces summary data from phase 1 trial of oral cr845 in hemodialysis patients with chronic kidney disease.Cara Therapeutics Inc - ‍phase 1 results showed that all four tablet strengths of oral CR845 were generally well-tolerated​.Cara Therapeutics- ‍overall,frequency of treatment emergent adverse events (teaes) in CR845-treated patients was similar to group administered placebo​.Cara Therapeutics-data to inform design of planned oral CR845 pruritus clinical program in non-dialysis ckd-ap population aimed to initiate later this year.  Full Article

Cara Therapeutics announces top-line results from phase 2B trial
Thursday, 29 Jun 2017 04:01pm EDT 

June 29 (Reuters) - Cara Therapeutics Inc ::Cara Therapeutics announces top-line results from phase 2B trial of oral CR845 in chronic pain patients with osteoarthritis of the hip or knee.Cara Therapeutics Inc - all tablet strengths well tolerated over eight-week treatment period.Cara Therapeutics Inc - 35 percent reduction in mean joint pain score for all patients at eight weeks with 5.0 mg dose.Cara Therapeutics Inc - statistically significant 39 percent reduction in mean joint pain score in hip patients at eight weeks with 5.0 mg dose.  Full Article

Cara receives breakthrough therapy designation from FDA for I.V. CR845
Friday, 23 Jun 2017 07:00am EDT 

June 23 (Reuters) - Cara Therapeutics Inc ::Cara receives breakthrough therapy designation from FDA for I.V. CR845 for the treatment of chronic kidney disease-associated pruritus in hemodialysis patients.  Full Article

Cara Therapeutics reports continuation of phase 3 trial of I.V. CR845 in postoperative pain
Wednesday, 21 Jun 2017 07:00am EDT 

June 21 (Reuters) - Cara Therapeutics Inc ::Cara Therapeutics reports continuation of phase 3 trial of i.v. Cr845 in postoperative pain following interim assessment.Cara Therapeutics - ‍based on guidance of idmc, trial will continue to test 2 doses of cr845 versus placebo in up to 450 patients undergoing abdominal surgery​.Cara Therapeutics Inc - trial will continue to test two doses of cr845 and aims to enroll up to 450 patients.Cara Therapeutics Inc - both doses of cr845 well tolerated.Cara Therapeutics Inc - trial completion expected in q4 of 2017 for cr845.  Full Article

Cara Therapeutics Q1 loss per share $0.81
Thursday, 4 May 2017 04:01pm EDT 

May 4 (Reuters) - Cara Therapeutics Inc ::Cara Therapeutics reports first quarter 2017 financial results.Q1 loss per share $0.81.Q1 earnings per share view $-0.74 -- Thomson Reuters I/B/E/S.Cara Therapeutics Inc - expects existing cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements into 2019.Qtrly total revenue $911,000 versus $7,000.  Full Article

Cara Therapeutics signs licensing deal with Vifor Fresenius, shares surge

Shares of Cara Therapeutics surged more than 20 percent on Wednesday after it signed a licensing agreement with Vifor Fresenius Medical Care Renal Pharma Ltd that could give the U.S. drug developer up to $470 million in milestone payments.